PankoMab-GEX™: Phase 1 Dose Escalation Study

NCT01222624 | Completed Phase 1 DMC

• 1 other identifier: GEXMab25101
• Study Type: interventional
• Target: 74
• Locations: 3 countries
• Sites: 4

Brief Summary

Prospective, open label, dose escalating, multicenter, phase I study measuring the safety, tolerability, and pharmacokinetics of PankoMab-GEX™ after intravenous administration in patients with locally advanced or metastatic solid cancers refractory to standard treatment. The effect of PankoMab-GEX™ on the development of antibodies and tumor response was also evaluated.

Conditions

Solid Tumors

Keywords

advanced solid malignancies

Outcome Measures

Primary Outcomes (5)

• Incidence of Treatment-Emergent Adverse Events assessed with the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE], Version 3.0

  Adverse events coded using Medical Dictionary for Regulatory Activities (MedDRA) version 13.1

  Until 28±2 days following the last infusion

• Incidence of Treatment-Emergent abnormal clinical laboratory parameters assessed with the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE], Version 3.0

  Analyzed in local clinical laboratories

  Until 28±2 days following the last infusion

• Changes in corrected QT interval (QTc) duration

  based on Electrocardiograms (ECG)

  Until 28±2 days following the last infusion

• Changes of left ventricular ejection fraction (LVEF)

  based on Multiple Gated Acquisition (MUGA) scan or Echocardiogram (ECHO)

  Until 28±2 days following the last infusion

• Eastern Cooperative Oncology Group (ECOG) Performance Status

  The ECOG Scale of Performance Status describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). The scale comprises six grades: 0 Fully active, able to carry on all pre-disease performance without restriction 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work 2. Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours 3. Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours 4. Completely disabled; cannot carry on any selfcare; totally confined to bed or chair 5. Dead

  Until 28±2 days following the last infusion

Secondary Outcomes (11)

• Pharmacokinetics (PK): Peak Plasma Concentration (Cmax)

  Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks

• Pharmacokinetics (PK): Minimum Drug Concentration (Cmin)

  Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks

• Pharmacokinetics (PK):Time to reach Cmax (tmax)

  Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks

• Pharmacokinetics (PK): Area under the curve (AUC)

  Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks

• Pharmacokinetics (PK): Apparent terminal serum half-life (t1/2)

  Assessment prior to and 2 min before the end of first infusion, 1 hr and 3 hrs after end of first infusion and 24 hrs after start of first infusion, on Day 2, Day 4, Day 7, Day 14, and then prior to and after end of each infusion up to 15 weeks

Study Arms (3)

PankoMab-GEX™, 3-weekly

EXPERIMENTAL

application, q3w

Drug: PankoMab-GEX™

PankoMab-GEX™, 2-weekly

EXPERIMENTAL

application q2w

Drug: PankoMab-GEX™

PankoMab-GEX™, weekly

EXPERIMENTAL

application q1w

Drug: PankoMab-GEX™

Interventions

PankoMab-GEX™ DRUG

Also known as: gatipotuzumab

PankoMab-GEX™, 2-weekly; PankoMab-GEX™, 3-weekly; PankoMab-GEX™, weekly

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female and age ≥ 18 yrs
• Histologically-confirmed TA-MUC1 positive measurable or non-measurable solid tumors according to RECIST criteria who failed standard therapy and for whom no further standard therapy is available (TA-MUC1 positivity assessed by PankoMab-GEX™ staining in immunohistology of the tumor).
• Failure of standard therapy or non-availability of standard therapy
• Patients must have received at least 1 standard chemotherapy during the course of the tumor disease
• All therapies must be completed 6 weeks (therapeutic monoclonal antibodies) or 4 weeks (all other anti-cancer agents) before start of study treatment and patients must have recovered from all prior therapy toxicities to at least CTCAE grade 1
• Performance status: Eastern Cooperative Oncology Group (ECOG) 0-1 and estimated life expectancy of \> 3 months
• Adequate organ function as assessed by the following laboratory parameters within 14 days prior to study drug application:
• Bone marrow function: hemoglobin ≥ 100 g/L; white blood cell count (WBC) ≥ 3.0 x 10\^9/L; absolute neutrophil count (ANC) ≥ 1.5x 10\^9/L; platelet count ≥ 100 x 10\^9/L
• Hepatic: aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤ 2.5 times upper limit of normal (ULN) (≤ 5 x ULN if hepatic metastases present); bilirubin ≤ 1.5 x ULN; alkaline phosphatase ≤ 5.0 times upper limit of normal (ULN)
• Renal: Calculated creatinine clearance \> 80 ml/min using the Modification of Diet in Renal Disease (MDRD) formula according to Levey 2005: Glomerular filtration rate (GFR) (ml/min/1.73 m²) = 186 x (serum creatinine /0,95)\^-1.154 x (age)\^-0.203 x (0.742 females) x (1.21 in black patients)
• Patients of both genders with procreative potential must use effective contraception while enrolled in the study and for at least 6 weeks after the last study drug infusion
• Written informed consent must be obtained prior to conducting any study-specific procedures

You may not qualify if:

• Antibody-based immunotherapy within 6 weeks and chemotherapy, radiation or other anti-cancer therapies within 4 weeks prior to study enrolment
• Any investigational agents at the study enrolment
• Concurrent anti-tumor therapy or concurrent immunotherapy
• Concurrent systemic steroids except topical (inhaled, topical, nasal), replacement therapy for the last 28 days. Steroids at low and stable dose (up to 20 mg prednisone) given for chronic disease are also permitted
• History of allergic reactions to previous antibody therapy
• Major surgery within 4 weeks prior entering the study and/or incomplete recovery from surgery or planned major surgery
• Documented history of active autoimmune disorders requiring systemic immunosuppressive therapy such as sarcoidosis, lupus erythematosus, rheumatoid arthritis, glomerulonephritis or systemic vasculitis (except autoimmune thyroiditis with only thyroid hormone replacement and stable disease \>1 year)
• Primary or secondary immune deficiency
• Clinically active infections \> CTCAE grade 2
• Prior allergic reaction to a monoclonal antibody (e.g. Trastuzumab, Cetuximab or Bevacizumab).
• Active hepatitis B or C; human immunodeficiency virus (HIV) seropositivity
• Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for ≥3 years will be allowed to enter the study.
• Uncontrolled medical condition considered as high risk for the treatment with an investigational drug including unstable diabetes mellitus, vena-cava-syndrome, chronic symptomatic respiratory disease.
• Brain metastasis or leptomeningeal involvement
• Symptomatic congestive heart failure (New York Heart Association \[NYHA\] 3 or 4); unstable angina pectoris within 6 months prior to enrollment; significant cardiac arrhythmia, history of stroke or transient ischemic attack within 1 year or left ventricular ejection fraction (LVEF) below the institutional range of normal on a baseline multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)

Sponsors & Collaborators

• Glycotope GmbH: lead

Study Sites (4)

Glycotope Investigational Site

Hamburg, D-20246, Germany

Location

Glycotope Investigational Site

Milan, 20132, Italy

Location

Glycotope Investigational Site

Milan, 20133, Italy

Location

Glycotope Investigational Site

Bellinzona, CH-6500, Switzerland

Location

Related Publications (1)

• Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas. Eur J Cancer. 2016 Aug;63:55-63. doi: 10.1016/j.ejca.2016.05.003. Epub 2016 Jun 7.

  PMID: 27285281 RESULT

MeSH Terms

Interventions

PankoMab-GEX

Study Officials

• Glycotope GmbH

  Glycotope GmbH

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 15, 2010
• First Posted: October 18, 2010
• Study Start: November 1, 2009
• Primary Completion: December 1, 2012
• Study Completion: May 1, 2013
• Last Updated: May 20, 2021

Record last verified: 2021-05

Locations

IT (2); CH (1); DE (1)